Top Page
Emyria Ltd
(Sydney:EMD)
Emyria Ltd (EMD) vs. iShares MSCI Australia ETF (EWA)
Emyria Ltd Business Overview & Revenue Model
Emyria Ltd Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 1.77M | 2.20M | 1.59M | 1.82M | 1.98M | 1.01M | Gross Profit |
| -172.42K | -167.55K | -3.32M | -4.41M | -1.58M | -2.79M | EBIT |
| -2.75M | -6.90M | -7.12M | -8.54M | -5.71M | -5.63M | EBITDA |
| -399.76K | -13.03M | -4.14M | -6.74M | -4.49M | -4.80M | Net Income Common Stockholders |
| -1.63M | -11.46M | -5.13M | -7.33M | -4.91M | -5.24M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 1.55M | 1.57M | 2.73M | 3.88M | 6.53M | 3.69M | Total Assets |
| 5.04M | 5.43M | 10.16M | 8.25M | 9.06M | 5.06M | Total Debt |
| 802.68K | 1.72M | 1.27M | 632.70K | 949.70K | 610.82K | Net Debt |
| -748.38K | 152.47K | -1.46M | -3.25M | -5.58M | -3.08M | Total Liabilities |
| 1.63M | 3.00M | 3.37M | 1.93M | 1.88M | 1.28M | Stockholders Equity |
| 3.41M | 2.43M | 6.79M | 6.32M | 7.18M | 3.78M |
| Cash Flow | Free Cash Flow | ||||
| -973.65K | -4.44M | -7.01M | -7.46M | -4.60M | -4.65M | Operating Cash Flow |
| -812.51K | -4.28M | -3.77M | -5.43M | -3.94M | -4.45M | Investing Cash Flow |
| -1.18M | -1.38M | -3.23M | -2.03M | -661.39K | -201.81K | Financing Cash Flow |
| 1.58M | 4.50M | 5.86M | 4.81M | 7.44M | 5.73M |
Emyria Ltd Technical Analysis
Emyria Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | AU$203.27M | ― | -37.20% | ― | ― | 32.02% | |
54 Neutral | $5.37B | 3.35 | -45.10% | 2.79% | 16.77% | -0.01% | |
44 Neutral | AU$41.35M | ― | -19.31% | ― | 72.25% | 43.66% | |
43 Neutral | $39.54M | ― | -75.39% | ― | ― | 44.29% | |
40 Neutral | AU$11.79M | ― | -74.80% | ― | -9.16% | 89.23% | |
36 Underperform | $3.32M | ― | -119.28% | ― | ― | 64.10% |
Emyria Ltd Corporate Events
Emyria Limited has announced promising six-month follow-up results from its treatment program for patients with treatment-resistant PTSD, showing significant symptom improvement and quality-of-life gains. The results highlight the effectiveness of Emyria’s structured, psychiatrist-led care model, which has shown to provide meaningful and sustained improvements in a real-world setting, positioning the company as a global leader in PTSD treatment.
Emyria Ltd has announced that David Dominic Pevcic has ceased to be a substantial holder in the company as of March 31, 2025. This change is due to the dilution of shares resulting from a placement, affecting over 20 million voting securities. The announcement reflects a shift in the company’s shareholder structure, which may influence its governance and strategic direction.
Emyria Limited reported significant clinical outcomes from its PTSD treatment program, with patients showing substantial improvements in symptoms and quality of life. The company also launched a treatment-resistant depression program, engaged with health funders for pilot programs, restructured its leadership, and expanded its treatment capacity by opening a new Empax Centre.
Emyria Limited has opened its second Empax Centre within Perth Clinic, a leading private mental health hospital in Western Australia, expanding its treatment capacity by 50%. This move is part of a broader strategy to meet growing national demand and align with healthcare funders’ requirements for evidence-based mental health therapies. The new centre will initially treat patients with PTSD and treatment-resistant depression, with plans for further expansion on the East Coast. The initiative reflects Emyria’s commitment to scalable, evidence-based care and its potential for lasting patient impact, supported by private insurers and major payers.
Emyria Limited has announced the issuance of 28,571,429 new fully paid ordinary shares at an issue price of $0.035 per share. This move allows the shares to be traded immediately under the exemption provided by section 708A(5) of the Corporations Act, indicating compliance with relevant legal provisions and enabling enhanced liquidity for stakeholders.
Emyria Limited announced a change in the director’s interest, specifically for Mr. Greg Hutchinson. The update includes the acquisition of 28,571,429 fully paid ordinary shares, 2,500,000 performance rights, and 5,000,000 unlisted options as part of a placement to raise $1 million and under the Company’s Employee Securities Incentive Plan. This change reflects Emyria’s strategic move to strengthen its financial position and incentivize its leadership, potentially impacting its market dynamics and stakeholder confidence.
Emyria Ltd has announced the issuance of unquoted equity securities, including 2.5 million performance rights and 7 million options exercisable at $0.051 each, expiring in March 2028. This move is part of an employee incentive scheme and is not intended for public trading on the ASX, potentially enhancing employee engagement and aligning interests with company performance.
Emyria Ltd has announced the quotation of 28,571,429 fully paid ordinary shares on the Australian Securities Exchange (ASX), effective March 28, 2025. This move is part of previously announced transactions and is expected to enhance the company’s financial flexibility, potentially impacting its market positioning and providing new opportunities for stakeholders.
Emyria Ltd announced that all resolutions presented at its General Meeting of Shareholders were successfully passed by a poll. This outcome reflects strong shareholder support for the company’s strategic decisions, including the ratification and approval of various share and option issuances. The resolutions are expected to enhance Emyria’s operational capabilities and align management incentives with shareholder interests, potentially strengthening its market position.